Cardiovascular status of childhood cancer survivors exposed and unexposed to cardiotoxic therapy.
about
The tell-tale heart: molecular and cellular responses to childhood anthracycline exposurePsychoneuroimmunology and cancer: a decade of discovery, paradigm shifts, and methodological innovationsSerum biomarkers for the detection of cardiac toxicity after chemotherapy and radiation therapy in breast cancer patientsUse of biomarkers for the assessment of chemotherapy-induced cardiac toxicity.Recruitment feasibility to a cohort study of endocrine and metabolic health among survivors of childhood brain tumours: a report from the Canadian study of Determinants of Endometabolic Health in ChIlDrEn (CanDECIDE).Diagnostic Strategies for Early Recognition of Cancer Therapeutics-Related Cardiac Dysfunction.Cardiovascular disease in adult survivors of childhood cancer.Endothelial health in childhood acute lymphoid leukemia survivors: pilot evaluation with peripheral artery tonometry.NT-proBNP as early marker of subclinical late cardiotoxicity after doxorubicin therapy and mediastinal irradiation in childhood cancer survivorsManaging chemotherapy-related cardiotoxicity in survivors of childhood cancers.Late morbidity in long-term survivors of childhood brain tumors: a nationwide registry-based study in FinlandRole of Interleukin-1 in Radiation-Induced Cardiomyopathy.Cardiac Safety of TGF-β Receptor I Kinase Inhibitor LY2157299 Monohydrate in Cancer Patients in a First-in-Human Dose Study.Late Cardiotoxicity in Aging Adult Survivors of Childhood Cancer.Echocardiographic Detection of Cardiac Dysfunction in Childhood Cancer Survivors: How Long Is Screening Required?Role of NT-proBNP in detection of myocardial damage in childhood leukemia survivors treated with and without anthracyclinesPharmacogenomics as a risk mitigation strategy for chemotherapeutic cardiotoxicity.Impaired mitochondrial function is abrogated by dexrazoxane in doxorubicin-treated childhood acute lymphoblastic leukemia survivors.Cranial irradiation as an additional risk factor for anthracycline cardiotoxicity in childhood cancer survivors: an analysis from the cardiac risk factors in childhood cancer survivors studyCardiac Outcomes in Adult Survivors of Childhood Cancer Exposed to Cardiotoxic Therapy: A Cross-sectional StudyCanadian Study of Determinants of Endometabolic Health in ChIlDrEn (CanDECIDE study): a cohort study protocol examining the mechanisms of obesity in survivors of childhood brain tumoursAnthracycline-induced cardiotoxicity: prospective cohort study from Pakistan.Treatment-related cardiotoxicity in survivors of childhood cancer.Anthracycline-induced cardiotoxicity: a review of pathophysiology, diagnosis, and treatment.Late Effects of Treatment of Pediatric Central Nervous System Tumors.Heart failure and chemotherapeutic agents.Cardiac complications in childhood cancer survivors treated with anthracyclines.Compulsory military service as a measure of later physical and cognitive performance in male survivors of childhood cancer.Young adult survivors of childhood acute lymphoblastic leukemia show evidence of chronic inflammation and cellular aging.Anthracycline or trastuzumab-related cardiotoxicity: do we have a predictive biomarker?The Future of Onco-Cardiology: We Are Not Just "Side Effect Hunters".Prevention of cardiotoxicity among survivors of childhood cancer.Late Cardiotoxicity: Issues for Childhood Cancer Survivors.Caring for cancer survivors: more than just checking the blood pressure and measuring the ejection fraction.Cardiotoxicity and cardiomyopathy in children and young adult survivors of hematopoietic stem cell transplant.Chemotherapy-induced cardiotoxicity in children.Home-Based Exercise Training Improves Left Ventricle Diastolic Function in Survivors of Childhood ALL: A Tissue Doppler and Velocity Vector Imaging Study.Two-Dimensional Speckle Tracking Echocardiography Detects Subclinical Left Ventricular Systolic Dysfunction among Adult Survivors of Childhood, Adolescent, and Young Adult Cancer.Cardiovascular disease risk in childhood cancer survivors.Early cardiac outcomes following contemporary treatment for childhood acute myeloid leukemia: a North American perspective.
P2860
Q26823592-324A3FFC-ED0E-4A93-862B-1E59F096A855Q27007708-0E2004CF-6AE7-43D0-92F1-2D134C848F73Q27007849-A032035E-DD4B-434A-B2DC-E7F355A3BF00Q27027354-15FAE48C-65D6-4256-A57C-980E0AD228DEQ30582316-73D24880-5050-48D3-ADD3-C73DB746F87BQ33565936-C29CD9EC-8A93-49B8-B332-60CE17DAAE92Q34042984-80CBF0AC-2917-4AFD-A17E-65C6510E9B8AQ34090658-1E48C8A6-C807-4625-BE06-97DEC8FE3EE6Q35557142-76C4F191-0292-42B0-BD68-DBC0C7477207Q35562745-828D6B71-0925-4B33-AE97-2A5BD2BC6FC1Q35788606-56635A4D-4179-4525-9294-2B742A696205Q35855691-73D09614-F8C4-4AD1-90D7-4B1A1FAC7983Q36073549-8B8DF126-1D0F-4827-8F8D-828EF28A508AQ36087880-2B92283F-2FA5-4F72-8ED7-73F66D022692Q36348525-0450CF6C-4833-44BD-A9E8-39F7915D64F1Q36416745-D4454487-718D-40EF-9075-32544C581D86Q36637796-5EF12A91-1E05-43AC-B25F-EB408832D492Q36649653-3A2026AF-E56A-4183-8D45-9AF539F81177Q36674961-7A6390B5-2291-4312-90A9-6FFFB8456EF5Q36732654-8A30B83F-49F4-4CD2-81AD-F7402F6A8CE7Q36939200-C8EF7958-6726-439B-AD4A-804B841D303CQ37342407-D9D840E5-045A-43F5-B30E-7C6251718607Q38156036-5EB18DE0-47AB-4E76-8FC4-018630972E83Q38205702-35E25072-970E-4857-8C36-939BA6F664C0Q38516808-8D22C8BE-5F57-43DF-97BE-D5E86F25D464Q38559133-2F5F3BF0-6DF9-44EC-80E7-65D3D08E7E88Q38588167-88C4EF3A-BFA4-4DD8-9ED1-EFFF71112281Q38677016-5D6F5B73-462C-4938-A73F-FA7CE0DD1236Q38707197-598FAB54-19CA-4F8F-B5FE-16DAF5F9AE54Q38727423-7CF40EE9-3AB2-4A18-9A77-BF9F71795409Q38816130-A7A2F73C-E134-4C21-8C80-5BF3BC39F020Q38824644-56FABB3F-394F-4296-BDC9-839454C3AD4FQ38845457-240AF978-ADDE-446F-9C15-BBA5E4E0E1B5Q38978062-DAB8040C-3BD1-447F-A224-3D2B9818D538Q39270177-47272E64-C145-423A-9D74-025D4F52A6A1Q39415815-C794FEE1-DAA6-466C-BB97-EED31839A4F2Q40745163-8F06949C-1F96-4362-B984-8F6656472729Q40872171-14DD12ED-0BA3-4D4F-8D84-766AF62F537FQ44882020-F9537444-5FAB-4EF9-8AB7-C5F3A159CA53Q46904082-E7EFE1DD-2F22-4EBC-9E83-AA58FB804F23
P2860
Cardiovascular status of childhood cancer survivors exposed and unexposed to cardiotoxic therapy.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
Cardiovascular status of child ...... xposed to cardiotoxic therapy.
@ast
Cardiovascular status of child ...... xposed to cardiotoxic therapy.
@en
type
label
Cardiovascular status of child ...... xposed to cardiotoxic therapy.
@ast
Cardiovascular status of child ...... xposed to cardiotoxic therapy.
@en
prefLabel
Cardiovascular status of child ...... xposed to cardiotoxic therapy.
@ast
Cardiovascular status of child ...... xposed to cardiotoxic therapy.
@en
P2093
P2860
P356
P1476
Cardiovascular status of child ...... exposed to cardiotoxic therapy
@en
P2093
Amy M Rovitelli
Andrea S Hinkle
Carol A French
Cindy Proukou
David C Landy
Gabriela Lopez-Mitnik
Louis S Constine
Steven E Lipshultz
Stuart R Lipsitz
Tracie L Miller
P2860
P304
P356
10.1200/JCO.2010.33.7907
P407
P577
2012-03-05T00:00:00Z